(AZN) AstraZeneca - Overview
Stock: Oncology, Cardiovascular, Respiratory, Immunology, Vaccines
| Risk 5d forecast | |
|---|---|
| Volatility | 35.5% |
| Relative Tail Risk | -3.26% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.06 |
| Alpha | 41.43 |
| Character TTM | |
|---|---|
| Beta | 0.168 |
| Beta Downside | 0.543 |
| Drawdowns 3y | |
|---|---|
| Max DD | 28.74% |
| CAGR/Max DD | 0.63 |
EPS (Earnings per Share)
Revenue
Description: AZN AstraZeneca January 26, 2026
AstraZeneca PLC (NASDAQ: AZN) is a global biopharmaceutical firm headquartered in Cambridge, UK, that discovers, develops, manufactures, and commercializes prescription medicines across oncology, cardiovascular-renal-metabolism, respiratory-immunology, vaccines, and rare-disease therapeutic areas. Its marketed portfolio includes blockbuster oncology agents such as Tagrisso, Imfinzi and Lynparza, metabolic drugs like Farxiga, and respiratory products such as Symbicort and Breztri, among dozens of other branded medicines.
In its most recent fiscal year (FY 2023), AstraZeneca reported revenue of **$44.2 billion**, an earnings-per-share (EPS) of **$2.90**, and a **research-and-development spend of $6.5 billion**, reflecting a 13 % YoY increase in R&D intensity. The company’s flagship oncology drug Tagrisso generated **$5.1 billion** in sales, while Farxiga contributed $4.4 billion, underscoring the continued importance of its cancer and metabolic pipelines. AstraZeneca also announced a strategic partnership with Tempus to build the largest multimodal foundation model for oncology and a quantum-computing collaboration with IonQ to accelerate drug-discovery workflows, both aimed at shortening time-to-market for new candidates.
Sector-wide, the pharmaceutical industry is being driven by an aging global population, rising prevalence of chronic diseases, and accelerating adoption of advanced therapies such as cell-based and gene-editing treatments, which together support a long-term growth outlook of 4-5 % CAGR for the market. AstraZeneca’s diversified product mix, strong pipeline (over 20 late-stage candidates), and high-margin specialty drugs position it to capture a meaningful share of this tailwind. **For a deeper dive into AZN’s valuation metrics and scenario analysis, the ValueRay platform offers a concise, data-driven toolkit.**
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income: 10.22b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA 2.21 > 1.0 |
| NWC/Revenue: -3.22% < 20% (prev -3.77%; Δ 0.55% < -1%) |
| CFO/TA 0.13 > 3% & CFO 14.57b > Net Income 10.22b |
| Net Debt (23.99b) to EBITDA (19.83b): 1.21 < 3 |
| Current Ratio: 0.94 > 1.5 & < 3 |
| Outstanding Shares: last quarter (3.12b) vs 12m ago 0.0% < -2% |
| Gross Margin: 81.90% > 18% (prev 0.81%; Δ 8109 % > 0.5%) |
| Asset Turnover: 53.86% > 50% (prev 51.98%; Δ 1.89% > 0%) |
| Interest Coverage Ratio: 8.32 > 6 (EBITDA TTM 19.83b / Interest Expense TTM 1.69b) |
Altman Z'' 1.29
| A: -0.02 (Total Current Assets 28.72b - Total Current Liabilities 30.62b) / Total Assets 114.07b |
| B: 0.10 (Retained Earnings 10.97b / Total Assets 114.07b) |
| C: 0.13 (EBIT TTM 14.10b / Avg Total Assets 109.05b) |
| D: 0.21 (Book Value of Equity 13.40b / Total Liabilities 65.36b) |
| Altman-Z'' Score: 1.29 = BB |
Beneish M -2.97
| DSRI: 1.08 (Receivables 15.18b/12.97b, Revenue 58.74b/54.07b) |
| GMI: 0.99 (GM 81.90% / 81.12%) |
| AQI: 0.97 (AQ_t 0.62 / AQ_t-1 0.64) |
| SGI: 1.09 (Revenue 58.74b / 54.07b) |
| TATA: -0.04 (NI 10.22b - CFO 14.57b) / TA 114.07b) |
| Beneish M-Score: -2.97 (Cap -4..+1) = A |
What is the price of AZN shares?
Over the past week, the price has changed by +0.39%, over one month by +12.64%, over three months by +16.02% and over the past year by +44.37%.
Is AZN a buy, sell or hold?
What are the forecasts/targets for the AZN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 113.5 | -44.4% |
| Analysts Target Price | - | - |
AZN Fundamental Data Overview February 21, 2026
P/E Forward = 18.2149
P/S = 10.05
P/B = 6.2683
P/EG = 1.0785
Revenue TTM = 58.74b USD
EBIT TTM = 14.10b USD
EBITDA TTM = 19.83b USD
Long Term Debt = 24.71b USD (from longTermDebt, last quarter)
Short Term Debt = 3.57b USD (from shortTermDebt, last quarter)
Debt = 29.70b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 23.99b USD (from netDebt column, last quarter)
Enterprise Value = 608.14b USD (584.18b + Debt 29.70b - CCE 5.74b)
Interest Coverage Ratio = 8.32 (Ebit TTM 14.10b / Interest Expense TTM 1.69b)
EV/FCF = 57.91x (Enterprise Value 608.14b / FCF TTM 10.50b)
FCF Yield = 1.73% (FCF TTM 10.50b / Enterprise Value 608.14b)
FCF Margin = 17.88% (FCF TTM 10.50b / Revenue TTM 58.74b)
Net Margin = 17.41% (Net Income TTM 10.22b / Revenue TTM 58.74b)
Gross Margin = 81.90% ((Revenue TTM 58.74b - Cost of Revenue TTM 10.63b) / Revenue TTM)
Gross Margin QoQ = 79.89% (prev 81.56%)
Tobins Q-Ratio = 5.33 (Enterprise Value 608.14b / Total Assets 114.07b)
Interest Expense / Debt = 1.59% (Interest Expense 472.0m / Debt 29.70b)
Taxrate = 11.41% (300.0m / 2.63b)
NOPAT = 12.49b (EBIT 14.10b * (1 - 11.41%))
Current Ratio = 0.94 (Total Current Assets 28.72b / Total Current Liabilities 30.62b)
Debt / Equity = 0.61 (Debt 29.70b / totalStockholderEquity, last quarter 48.67b)
Debt / EBITDA = 1.21 (Net Debt 23.99b / EBITDA 19.83b)
Debt / FCF = 2.28 (Net Debt 23.99b / FCF TTM 10.50b)
Total Stockholder Equity = 45.08b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.38% (Net Income 10.22b / Total Assets 114.07b)
RoE = 22.68% (Net Income TTM 10.22b / Total Stockholder Equity 45.08b)
RoCE = 20.20% (EBIT 14.10b / Capital Employed (Equity 45.08b + L.T.Debt 24.71b))
RoIC = 16.65% (NOPAT 12.49b / Invested Capital 74.99b)
WACC = 6.29% (E(584.18b)/V(613.88b) * Re(6.54%) + D(29.70b)/V(613.88b) * Rd(1.59%) * (1-Tc(0.11)))
Discount Rate = 6.54% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 81.65 | Cagr: 0.03%
[DCF Debug] Terminal Value 85.95% ; FCFF base≈9.21b ; Y1≈10.39b ; Y5≈14.00b
Fair Price DCF = 109.7 (EV 364.15b - Net Debt 23.99b = Equity 340.16b / Shares 3.10b; r=6.29% [WACC]; 5y FCF grow 14.89% → 2.90% )
EPS Correlation: 71.93 | EPS CAGR: 104.0% | SUE: N/A | # QB: 0
Revenue Correlation: 94.73 | Revenue CAGR: 8.57% | SUE: N/A | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.23 | Chg30d=-0.033 | Revisions Net=+1 | Analysts=2
EPS next Year (2026-12-31): EPS=5.09 | Chg30d=-0.062 | Revisions Net=-1 | Growth EPS=+10.9% | Growth Revenue=+6.0%